Call Box is thrilled to announce the release of an exciting new feature, Call Tags. This feature is set to transform the way healthcare practices and professionals manage their calls, offering immediate benefits and improved efficiency.
DALLAS, Nov. 9, 2023 /PRNewswire-PRWeb/ — Call Box, a leader in innovative call management solutions, is thrilled to announce the release of an exciting new feature, Call Tags. This feature is set to transform the way healthcare practices and professionals manage their calls, offering immediate benefits and improved efficiency.
Call Tags, the latest enhancement from Call Box, allow easily identifiable tags to be placed on each call recording based on specific topics or phrases mentioned by the patient. With Call Tags, you can now easily identify and prioritize calls, making it simpler to find and access critical information from your conversations.
Furthermore, this enhanced feature allows users to search for calls, via Call Box’s Search for a Call feature, by tag for a quicker and simpler user experience. This enables healthcare practices to quickly sort through patient calls when building outbound campaigns, following up on urgent requests, and finding any missed appointment opportunities with high value.
“Call Tags represent a significant leap forward in call management. With this innovative feature, we empower our clients to harness the power of organization and efficiency,” states Executive Vice President of Product and Marketing, Jackie Bowers. “Call Tags streamline the process of finding and categorizing calls, ultimately saving valuable time and ensuring that crucial conversations are never missed. We believe that Call Tags will revolutionize the way professionals across the healthcare industry manage their calls, providing immediate, tangible benefits.”
The initial category of Call Tags being introduced is Procedure Tags. These tags are automatically generated from transcriptions and designed to identify medical procedures mentioned by the patient. With Procedure Tags, professionals can effortlessly search and categorize calls related to specific medical procedures, saving time and increasing productivity. Call Tags will be available for the following industries: Dental, Veterinary, Orthopedics, and Plastics. We will continue to expand our list of supported industries in the future.
Call Box prides itself on being the healthcare industry’s leader when it comes to call tracking and phone handling solutions. Being at the forefront of technology, Call Box continues to break barriers and find solutions to generate optimal phone performance for its clients.
About Call Box
As the leading provider of comprehensive phone solutions, Call Box believes the phone should be an asset to your organization, not an overwhelming liability to manage. Being top-notch on the phone shouldn’t be complicated or time-consuming. That’s where Call Box comes in. Call Box leverages human reviewers and artificial intelligence to track, review, and analyze 100% of the calls generated by thousands of healthcare practices. This allows managers to gain in-depth, actionable insight into the outcome of their calls to connect with more patients, improve caller experience, and convert more appointments opportunities.
For more information regarding Call Box, please contact us at [email protected].
Founders First CDC Awarded $25,000 to Veteran-Owned Small Business Owners Across The Country
SAN DIEGO, Nov. 9, 2023 /PRNewswire-PRWeb/ — Founders First CDC (Founders First), a national 501(c)(3) non-profit organization that empowers expansion in diverse founder-led, revenue-generating businesses, is pleased to announce the Veteran business recipients of its 2023 Stephen L. Tadlock Fund – a grant program to support U.S. veteran small business owners. The recipients had to meet specific qualifications to receive their grants, including: the company’s founder must be a U.S. military veteran, have an active U.S.-based business, and employ between 2 and 50 employees.
“We’ve established the Stephen L. Tadlock Fund for Veteran Business Owners in honor of my brother, Stephen L. Tadlock, a U.S. Navy Veteran. This $25,000 fund is a testament to our support for the vital contributions of Veteran entrepreneurs within the small business community. Having served our country through the military, their commitment inspires us. We’re fully committed to their success and hope this micro-grant can have a lasting impact on our economy.” says Kim Folsom, Founder and CEO of Founders First.
The purpose of the grant is to provide micro-investments to veterans who own and operate small businesses. The $25,000 grant has been awarded to 25 veteran recipients who received $1,000 each, which will help aid in their employer-based small businesses.
Since launching, Founders First CDC has awarded more than $1,000,000 to minority and underserved business owners throughout the United States with a focus on Texas, Chicago, Southern California, Twin Cities, Pennsylvania and New Jersey.
“Programs like Founders First CDC are the beacons of hope we wish every Veteran business owner could discover. This program is not just providing essential funding to aspiring business owners but leveling the playing field for diverse-led businesses through their non-profit business accelerator programs. We proudly stand as partners, and today, we extend our warmest congratulations to the 25 veteran grant fund recipients. Let each of their journeys inspire and motivate us all to reach new heights of success.” Traci Cole, Director of Southern California Veterans Business Outreach Center.
Congratulations to the 25 recipients of the 2023 Stephen L. Tadlock fund:
Quay Eady Consulting LLC
Tutor Doctor Ponte Vedra Beach
Outright Fitness LLC
Blissful Life Consulting LLC
MFH Group
Go Digital Hero LLC
A simple Organizing & Moving Company, LLC.
Spark Movement Academy
The Brand Amplifiers LLC
Harvesting Hands Homestead LLC
Connection Point Services, LLC
Let’s Chow
Snakebyte Media
Dolo Finance
Brotallion
AgTechLogic
Family First solution cdc
Poprouser Inc.
House of Huebris
HDO Health
Sponsor Match
Harden Enterprise Services LLC
Waiea Water Distributors LLC
Stampley Technology & Management, LLC
Aribaro Company
The judging committee for the Stephen L. Tadlock Grant includes a panel of distinguished veterans, representing multiple branches of service.
“As a finalist for the 2022 Stephen L. Tadlock Veteran grant, the funds enabled us to acquire essential equipment for our business. We are appreciative of all the assistance Founders First CDC provides to the Veteran business community, as it has assisted us in finding new ways to grow our business through our year-over-year growth” says Quinton McNair, Founder of StruggleBeard Bakery, U.S. Army.
According to the latest U.S. Census Bureau’s survey of small business owners, there are more than 2.5 million Veteran majority-owned businesses in the U.S. that employ more than 5 million individuals. As a result, these businesses generate a revenue of more than $1.14 trillion, and account for an annual payroll of $195 billion.
Founders First programs guide business owners through the process of achieving accelerated growth through curriculum, hands-on assignments, and expert coaching. To learn more about Founders First programs and grant qualifications, visit www.foundersfirstcdc.org.
About Founders First CDC
Founders First CDC is a non-profit 501c3 that was founded in 2015 and has received significant support from the regional community reinvestment banks to empower diverse founder-led, revenue-generating small businesses through three primary programs: (1) Founders Challenge; (2) Founders Bootcamp; and (3) Founders FastPath. By building recurring revenues, tech-enablement, and essential solution focus, Founders First serves as a catalyst for positive change to entrepreneurs of color and female founders to become leading employers in their communities. Learn more at www.foundersfirstcdc.org.
“It is an honor to be recognized for our innovations in predictive analytics for drug development for a second consecutive year,” said Dr. Jo Varhsney, Founder and CEO of VeriSIM Life. “This award highlights the ongoing positive changes that VeriSIM and BIOiSIM are making in the life sciences industry and drug development pipeline that will make a positive difference for doctors and their patients.”
Earlier this year, VeriSIM announced a new partnership with Clarivate— a leading global information services provider, to further expand the company’s capabilities in accelerating and de-risking drug development. Working together, VeriSIM and Clarivate have now released a new Translational Index Dashboard product for customers to accelerate early scientific investigation powered by Clarivate data and VeriSIM Life’s AI platform.
Recently, the company also conducted a client collaboration focused on optimizing treatments for substance use disorders by improving the accuracy of predictions for drug partitioning into brain tissue crossing the blood brain barrier. Using BIOiSIM, the team demonstrated prediction accuracy exceeding the industry standard threshold for reliability and identified ~20,000 molecules capable of blood brain barrier permeability and disposition into the brain.
“Our ever-growing number of client collaborations and partnerships is indicative of an industry-wide desire for positive changes and acceleration in the drug development pipeline,” said Varshney. “We’re proud to be a part of a community that is willing to work together to improve what we’re all doing in order to achieve better patient outcomes.”
VeriSIM’s work is being honored alongside other major breakthroughs in life sciences and biotechnology from ThermoFisher, Acumen Pharmaceuticals, Colossal Biosciences, Guardant Health, Mission Bio, Travere Therapeutics, Vaxess Technologies, Waters, and more.
The mission of the annual BioTech Breakthrough Awards program is to conduct the industry’s most comprehensive analysis and evaluation of the top technology companies, solutions, and products in the life sciences and biotechnology industry today. This year’s program attracted thousands of nominations coming in from all over the world.
About VeriSIM Life
VeriSIM Life has developed a sophisticated computational platform that leverages advanced AI and ML techniques to improve drug discovery and development by significantly reducing the time and money it takes to bring a drug to market. BIOiSIM® is a first-in-class ‘virtual drug development engine’ that offers unprecedented value for the drug development industry by narrowing down the number of drug compounds that offer anticipated value for the treatment or cure of specific illnesses or diseases. The platform predicts the likelihood of a candidate’s success in clinical trials early in the preclinical stage, while reducing unnecessary experimentation and better informing key program decisions. For more information, visit www.verisimlife.com.
About BioTech Breakthrough
Part of Tech Breakthrough, a leading market intelligence and recognition platform for global technology innovation and leadership, the BioTech Breakthrough Awards program is devoted to honoring excellence in life science and biotechnology solutions, services and companies. The BioTech Breakthrough Awards provide public recognition for the achievements of biotechnology companies and products in categories including BioPharma, Genomics, Therapeutics, Food Science and BioAgriculture, and more. For more information visit BioTechBreakthroughawards.com
This collaboration brings together NovaSterilis’ deep expertise of decellularization and terminal sterilization of medical devices in their final packaging, using scCO2 technologies and Dr. Spector’s extensive experience in plastic and reconstructive surgery.
“I’m pleased to collaborate with NovaSterilis on another CAT grant,” said Dr. Jason Spector. “We will be able to leverage the knowledge gained from our previous work on the decellularization and terminal sterilization of costal cartilage. This opportunity has the potential to improve patient outcomes where soft tissue regeneration is necessary.”
The project addresses the need for a permanent, regenerative treatment in the global $6.7 billion USD dermal/soft tissue filler market. Today’s solutions are temporary and require expensive regularly scheduled medical treatments. The allograft adipose matrix dermal filler developed through the Cornell University CAT holds the promise to be a tremendous improvement in the standard of care and a reduction in cost to the healthcare system.
“We are thrilled to collaborate with Dr. Spector on this exciting project,” said Tony Eisenhut, CEO of NovaSterilis. “Our combined efforts have the potential to make a significant impact in regenerative medicine, ultimately benefiting patients and reducing costs associated with multiple treatments.”
To fulfill this engagement, NovaSterilis engaged two commercial partners in the project: Alamo Biologics (San Antonio TX) and Australian Biotechnologies (Sydney Australia) will provide manufacturing, distribution, and marketing insights, as well as years of clinician feedback on the project. These partners have over 50 years of combined experience using the scCO2 technology platform across multiple markets, including healthcare, tissue engineering, regenerative medicine, and medical device sterilization. This commercial experience coupled with the clinical and translational research knowledge of Dr. Spector will be central to the development of an integrated process that creates a structurally stable, decellularized allograft adipose matrix with preserved endogenous growth factors.
“NovaSterilis has partnered with some of the best clinical and manufacturing teams in the industry to fulfill our goal of providing scCO2 technologies that meet or exceed the highest standards for product safety and performance,” Eisenhut added.
About NovaSterilis: NovaSterilis is a leading innovator in supercritical carbon dioxide technology, dedicated to advancing environmentally friendly and efficient solutions for a wide range of applications, including tissue processing, sterilization, and decellularization of regenerative medicine matrices. With a commitment to sustainability and innovation, NovaSterilis aims to transform industries and improve lives through the power of supercritical carbon dioxide. For more information visit http://www.novasterilis.com
About Dr. Jason Spector, M.D.: Jason A. Spector, M.D., F.A.C.S. is the Chief of the Division of Plastic and Reconstructive Surgery, and a Professor of Surgery and Otolaryngology at Weill Cornell Medicine, and Adjunct Professor in the Meinig School of Biomedical Engineering at Cornell University. He is a nationally recognized board-certified plastic surgeon specializing in reconstructive microsurgery of the head and neck, breast, and lower extremities, as well as aesthetic surgery. Dr. Spector is the Director and Principal Investigator of the Laboratory for Bioregenerative Medicine and Surgery at Weill Cornell Medicine. His lab focuses on novel approaches for tissue engineering, wound healing, and precision medicine, as well as the development of various translational technologies from bench to bedside.
About Alamo Biologics: Alamo Biologics is a full-service tissue bank offering the highest quality allografts and biologics for hundreds of surgical and regenerative applications. Alamo’s turn-key services include manufacturing, storage, and distribution of allograft tissue; research and development, contract manufacturing, and biologic storage facilities. Alamo strives to provide the highest standard in allograft tissue while continually honoring the gift of donation. For mor information visit https://alamobiologics.com/.
About Australian Biotechnologies: Australian Biotechnologies is the largest biological tissue processor in Australia, producing over 20,000 bone and tissue allograft products annually. Working with key Australian Donation Partners, our allografts offer life enhancing possibilities in orthopedic, sports medicine, spine, foot and ankle, reconstructive trauma, oral and dental procedures. Headquartered in Sydney Australia and supplies allografts to Australia and New Zealand. For more information visit www.ausbiotech.com.au.
About Cornell University: Cornell University is a world-class research institution known for the breadth and rigor of its curricula, and an academic culture dedicated to preparing students to be well-educated and well-rounded citizens of the world. Its faculty, staff and students believe in the critical importance of knowledge—both theoretical and applied—as a means of improving the human condition and solving the world’s problems. With campuses in Ithaca, New York and New York City, and a location in Doha, Qatar, Cornell is a private, Ivy League research university and the land-grant institution of New York State.
AboutNew York State Center for Advanced Technology: NYS CAT is a NYSTAR-supported program to encourage greater collaboration between private industry and universities in the development and application of new technologies. The CAT program, created in 1983, facilitates a continuing program of basic and applied research, development, and technology transfer in multiple technological areas, in collaboration with and through the support of private industry. CATs play a critical role in spurring technology-based applied research and economic development in the state; promoting national and international research collaboration and innovation; and leveraging New York’s research expertise and funding with investments from the federal government, foundations, businesses, venture capital firms and other entities. The Center for Life Science Enterprise at Cornell University, Cornell’s CAT, pursues programs addressing the economic development needs of New York’s biotech industry, partnering with companies in fields including bioengineering, diagnostics, medical devices, therapeutics, agriculture, and veterinary medicine since 1986.
“Code Ocean’s cloud-native platform for collaborative and trusted science guarantees reproducibility, automates access to tools and data, and speeds up discovery,” said Simon Adar, Co-founder and CEO, Code Ocean. “The platform brings together decision-makers, research IT, coding, and domain scientists in one collaborative space, and integrates with the existing software stack and infrastructure. It offers an important advantage to biotechs and pharma — it automatically traces the path of research data, mapping each step in a detailed lineage graph. Code Ocean’s provenance tracking provides full knowledge of the path the various science teams took during discovery, making each stage of computation fully reproducible with a single click.”
The mission of the annual BioTech Breakthrough Awards program is to honor excellence and recognize the creativity, hard work and success of companies, technologies and products within the field of biotechnology. The Biotech Breakthrough Awards aims to perform the most comprehensive evaluation of life sciences and biotechnology tools, services and companies today, with nominations coming in from the best and brightest biotechnology innovators around the world across a broad set of categories, including BioPharma, Genomics, Therapeutics, Immunology, BioAgriculture, BioIndustrial, Data & Analytics.
Code Ocean is a cloud-native research data and computing hub that serves all computational methods, including interactive analysis. By centralizing research data on a central platform for organizing the computational stage, Code Ocean unifies disparate groups, shares data and knowledge, and ensures the implementation of best practices. Code Ocean’s centralized platform tracks the path of research from raw data to results, boosting productivity for researchers and enabling them to focus on the science with a provable path. Code Ocean’s automated research platform guarantees the traceability and reproducibility of any result so scientific discoveries can be completely trusted by decision makers. It provides visibility for IT/VP level managers to clearly see the progress, and for C-level approvers, to understand how conclusions were reached.
“Code Ocean organizes the creative chaos inherent in computational science by providing one end-to-end platform for data and computational research in the wet and dry lab,” said Ram Dayan, Co-founder and Chief Technology Officer, of Code Ocean. “Our platform offers automation of best practices for data computation through an open platform with no vendor lock-in, meaning that it works with any Open Source language, API, data visualization tool, cloud computing/data source, computational package, and interactive development environment. Our Capsules offer exportable access to all levels of code and data, so all software, results, or methods are fully available outside Code Ocean.”
Code Ocean solves the problem of creative chaos in scientific discoveries. It’s your digital lab for faster, trusted computational science — the first and only integrated science library and workbench that guarantees reproducibility and speeds up discovery. Bringing together decision-makers, research IT, coding, and domain scientists in one shared, collaborative space, it provides a single pane of glass delivering end-to-end visibility, traceability, and reusability. Code Ocean keeps all your data, results, development environments, pipelines, AI/ML, no-code applications, and visualizations in one place as connected data products.
Executives from Financial Industry Regulatory Authority, Subway, Macy’s, Inc., Conair LLC, Marcum, Schulte Roth & Zabel LLP & Hackensack Meridian Health Recognized for their Achievements
NEW YORK, Nov. 9, 2023 /PRNewswire-PRWeb/ — NewYorkCIO announced the winners of its 2023 ORBIE® Awards. NewYorkCIO recognized technology executives in seven key categories – Leadership, Global, Large Enterprise, Enterprise, Large Corporate, Corporate, & Healthcare. The Awards were presented at the New York ORBIE Awards at Ziegfeld Ballroom.
“Member-led, non-commercial programs like the ORBIE Awards, build meaningful professional relationships with colleagues facing similar challenges, solving problems and avoiding pitfalls,” said Andrea Markstrom, NewYorkCIO Chair. “Successful leaders understand the ‘superpower’ of trusted relationships. In any gathering of technology leaders, the answer is in the room.”
The 2023 New York ORBIE Award winners are:
Steven Randich, EVP & CIO, Financial Industry Regulatory Authority received the Leadership ORBIE.
Donagh Herlihy, CDO & CIO, Subway received the Global ORBIE for organizations over $12 billion annual revenue & multi-national operations.
Laura Miller, CIO, Macy’s, Inc. received the Large Enterprise ORBIE for organizations over $12 billion annual revenue.
Jon Harding, SVP, Global CIO, Conair LLC received the Enterprise ORBIE for organizations over $2.5 billion annual revenue.
Peter Scavuzzo, Principal, CIO & CDO, Marcum received the Large Corporate ORBIE for organizations over $1 billion annual revenue.
Andrea Markstrom, CIO, Schulte Roth & Zabel LLP received the Corporate ORBIE for organizations up to $1 billion annual revenue.
Mark Eimer, SVP, Associate CIO & CTO, Hackensack Meridian Health received the Healthcare ORBIE for hospitals and healthcare organizations.
The ORBIE Awards is the premier technology executive recognition program in the United States. Since inception in 1998, over 700 technology leaders have received the prestigious ORBIE Award. The ORBIE honors chief information officers who have demonstrated excellence in leadership. Finalists and winners are selected by an independent peer review process, led by prior ORBIE recipients, based upon:
Leadership and management effectiveness
Business value created by technology innovation
Engagement in industry and community endeavors
The New York ORBIE Awards keynote was delivered by Anna Ransley, Chief Digital Information Officer, Quaker Houghton, who was interviewed by Robert Field, Board Member, Senior Advisor, RAVIA Global Services. Nearly 450 guests attended, representing leading Greater New York organizations and their technology partners.
The 2023 New York ORBIE Awards was made possible by the following sponsors:
Bronze sponsors: Between Pixels, Authority Partners, Aladdin by BlackRock, Bourntec Solutions, Box, CDI, Druva, EY, Infosys, Juniper Networks, Microsoft, Protiviti, Pure Storage, Slalom
Media partner: Crain’s New York Business
National partner: Year Up
About NewYorkCIO
NewYorkCIO is the preeminent peer leadership network of Greater New York chief information officers. NewYorkCIO is one of over 30 chapters of the Inspire Leadership Network, a national membership organization comprised exclusively of CIOs from public and private businesses, government, education, healthcare and nonprofit institutions.
Achieve your leadership potential through NewYorkCIO: www.NewYorkCIO.org
“We are thrilled to have paid off our loan facility on an accelerated basis, well before the term date,” said José Eduardo Vidal, Ph.D., Chief Executive Officer of CytoImmune Therapeutics. “This exemplifies our disciplined financial management and ability to execute on our long-term strategic goals. The Banco Popular loan facility provided critical funding during a key growth phase for CytoImmune. We are grateful for their support and look forward to continuing our partnership.”
“We assisted CytoImmune with the idea of using Act 60 incentives as collateral for financing,” said Aurelio Fuentes, founding partner of DECA Analytics, who advised CytoImmune on the transaction. “This concept is providing companies the ability to grow and expand their business and drive economic activity on the Island. In fact, we believe it makes so much sense that we have launched a fund to enable more efficient financing for innovative projects like that of CytoImmune.”
The accelerated repayment of this loan positions CytoImmune for continued success as the company expands its impact on the cell therapy field. In addition to advancing its own allogeneic NK cell therapy pipeline, CytoImmune aims to enable other developers to accelerate innovative treatments to patients by providing manufacturing services through its Puerto Rico site.
“The success of local companies like CytoImmune highlights the immense potential that Puerto Rico has as a biotechnology center,” said Secretary of Economic Development and Commerce of Puerto Rico, Manuel Cidre. “DDEC will remain committed to supporting the growth of this important and constantly growing industry and with innovative companies like CytoImmune that drive advances in cell therapy and at the same time they create high-quality jobs in Puerto Rico.”
CytoImmune remains committed to driving innovation in cell therapy and transforming outcomes for cancer patients worldwide. CytoImmune’s future plans include expanding its research portfolio, initiating new clinical trials, and fostering collaborations to usher in the next wave of cell-based treatments. The early loan payoff serves as a springboard, propelling CytoImmune into its next phase of growth and innovation.
About CytoImmune Therapeutics:
CytoImmune Therapeutics is at the forefront of a novel natural killer cell therapy for lung cancer, currently in phase 1 clinical trials. In addition, we are now offering cell therapy development and clinical manufacturing services to both biotechnology companies and academia. Our state-of-the-art clinical cell manufacturing facility in Toa Baja, Puerto Rico, is custom built to support the development and commercialization of cutting-edge T cell or NK cell therapies. At CytoImmune, we are dedicated to fostering collaborations that drive the future of cell therapy and improve the lives of cancer patients. Discover how our expertise in cell therapy development and clinical manufacturing can accelerate your path to success. For additional information, please visit: Cytoimmune.com.
About DECA Analytics:
DECA Analytics is recognized as Puerto Rico’s foremost advisory firm, expertly guiding businesses in both initiating and broadening their operations within the island. With profound expertise in Act 60-2019 and its predecessors, namely Act No. 73-2008, Act No. 74-2010, and Act No. 20-2012, DECA Analytics ensures that corporations fully capitalize on the Island’s tax incentives. The firm’s team, an assembly of financial, operational, legal, and growth strategists, boasts unparalleled knowledge of Puerto Rico’s intricate business environment. DECA Analytics distinguishes itself by offering strategic investment support, ensuring rigorous compliance, adeptly structuring capital, and providing access to both low-cost financing programs and non-dilutive capital. Their methodology is rooted in a comprehensive approach, merging precise quantitative analytics with seasoned qualitative insights, guaranteeing efficient processes and maximized fiscal incentives. As pivotal contributors to Puerto Rico’s economic advancement, DECA Analytics excels in the generation and monetization of Puerto Rico tax credits, while adeptly navigating grant funding provisions under Act 60. In essence, DECA Analytics is committed to facilitating corporate success within Puerto Rico’s dynamic business environment. For additional information, please visit:Deca-Analytics.com.
About the Puerto Rico Innovation Fund:
The Puerto Rico Innovation Fund (PRIF) offers targeted financing to innovative companies in Puerto Rico engaged in R&D activities. Dedicated to bolstering Puerto Rico’s economic growth, PRIF supports innovation, facilitating the development of new products and technologies. This focus not only drives business expansion and exports but also promotes job creation. To ensure the viability of its loans, PRIF takes liens on unique collateral available to qualified companies in Puerto Rico including future tax credits and grants, securing both principal and interest repayments. A standout feature of PRIF is its provision of non-dilutive capital, a previously scarce resource for companies engaged in R&D, and especially for those operating in Puerto Rico. This structure allows companies to maintain their equity while accelerating their R&D efforts. In essence, PRIF is pivotal in championing Puerto Rico’s innovators through strategic financial support. For additional information, please visit:PRInnovationFund.com
Recipients of this prestigious award were nominated by their peers, and it is a highly selective list. Those who are among the very best in their specialties are chosen for inclusion.
BEVERLY HILLS, Calif., Nov. 9, 2023 /PRNewswire-PRWeb/ — Dr. David Yamini has been selected as a 2023 Top Doctor® by Castle Connolly. Dr. Yamini is an accomplished physician who is double board-certified in gastroenterology and internal medicine. He serves patients in Santa Monica and Beverly Hills, CA, treating diseases and disorders of the digestive system. Dr. Yamini’s medical education, training, hospital appointments and disciplinary history were rigorously screened by the Castle Connolly physician-led research team. Castle Connolly publishes its list of Top Doctors at http://www.castleconnolly.com and in a wide variety of partner publications, magazines and affiliate websites. Around 7% of the nation’s top board-certified, licensed physicians have been selected as Castle Connolly Top Doctors in their regions for their specialties. Individuals do not and cannot pay to be selected as a Castle Connolly Top Doctor. Dr. David Yamini offers advanced diagnostic and therapeutic procedures and has established a reputation as one of the best Los Angeles gastroenterologists and liver disease specialists. Dr. Yamini offers expertise in issues involving the digestive tract, biliary system, liver and pancreas, with a proficiency in endoscopic retrograde cholangiopancreatography (ERCP). He takes a comprehensive approach to diagnosing and treating patients with all types of gastrointestinal (GI) problems and disorders that affect the small and large intestine, stomach, esophagus, gallbladder, liver and pancreas, including inflammatory bowel disease (Crohn’s, ulcerative colitis), indigestion (dyspepsia), small intestinal bacterial overgrowth (SIBO) and irritable bowel syndrome (IBS). Dr. Yamini provides his patients with a superior level of compassionate and attentive personalized care.
In the active phase of TED, the main symptoms include inflammation and increased amounts of tissue, muscles, and fat behind the eye, causing the eyeballs to bulge outward. If the eye is pushed far enough forward, the eyelids may not close properly when blinking and sleeping. In severe cases, the inflammation and enlargement of the tissues, muscles, and fat behind the eye compresses the optic nerve, causing vision loss.
Because many individuals with TED are more likely to develop depression and anxiety, during TED Awareness Week, Prevent Blindness will also debut a new episode in the Focus on Eye Health Expert Series, “Thyroid Eye Disease and Mental Wellness.” Neuro-ophthalmic conditions expert Prem Subramanian, MD, PhD, Clifford R. and Janice N. Merrill Endowed Chair in Ophthalmology and Vice Chair for Academic Affairs at Sue Anschutz-Rodgers Eye Center, UCHealth, discusses TED, its potential impact on mental health, and the importance of patient and healthcare provider communication to help improve health outcomes.
Because art therapy has been shown to help people improve their mental, emotional and even physical wellness, Prevent Blindness offers TED patients and care partners the Prevent Blindness Art Therapy Program, recently concluding its third session. This unique, no-cost program is thoughtfully designed to build community and connections among people who are affected by TED and provide the opportunity to create art using a variety of artistic media to express thoughts and feelings. This program is also supported by funding from Amgen and Viridian Therapeutics.
“Now in our 4th consecutive year, we are proud to continue to educate the public and provide patients and care partners with support for Thyroid Eye Disease,” said Jeff Todd, Prevent Blindness president and CEO. “Our goal is to provide comprehensive TED resources to empower patients, and encourage them to discuss their diagnosis, as well as any changes in mental health, to help limit the impact that TED may have on their health and quality of life.”
About Prevent Blindness Founded in 1908, Prevent Blindness is the nation’s leading volunteer eye health and safety organization dedicated to fighting blindness and saving sight. Focused on promoting a continuum of vision care, Prevent Blindness touches the lives of millions of people each year through public and professional education, advocacy, certified vision screening and training, community and patient service programs and research. These services are made possible through the generous support of the American public. Together with a network of affiliates, Prevent Blindness is committed to eliminating preventable blindness in America. For more information, visit us at PreventBlindness.org, and follow us on Facebook, X, Instagram, Threads, LinkedIn and YouTube.
Media Contact
Sarah Hecker, Prevent Blindness, 312.363.6035, [email protected], PreventBlindness.org
At Options, the care team of licensed medical providers and health coaches work together to create customized weight loss plans tailored to patients’ individual needs, aspirations, and lifestyles. Not only does this approach help patients achieve weight loss success, but it also provides invaluable education, guidance, and support needed to manage a healthy weight for years to come.
The Arlington Heights comprehensive care team is honored to bring a new standard of compassionate medical weight loss care to NW Chicago individuals looking to lose weight and improve their overall health.
The clinic cordially invites the communities of Arlington, Heights, Barrington, Buffalo Grove, Elk Grove, Deer Park, Des Plaines and surrounding communities to join in celebrating the clinic’s grand opening Nov. 21, 2023 from 5:30 – 7:00 p.m.. The grand opening will have refreshments and special giveaways to celebrate.
Options’ comprehensive approach to weight loss is what makes it different. “At Options, we’re approaching weight loss and wellness from all angles. We are equipping you with the knowledge to make empowered decisions and take ownership of the path to freedom that you carve out. You will never walk out of our clinic with a meal or medications and be left to figure it out on your own. We position each patient with a team of specialists that rally around you and support you all along the way,” said Dr. Katrina Mattingly, Chief Medical Officer of Options Medical Weight Loss.
Learn what makes Options Medical Weight Loss different in this short video.
About Options Medical Weight Loss: Options Medical Weight Loss was founded in 2014 in Chicago, Illinois, and has since opened locations throughout Illinois, Ohio, Florida, Arizona, and now Indiana, with continued plans to expand to more states. Options Medical Weight Loss has helped more than 50,000 patients achieve their weight loss goals.
To learn more about the new Arlington Heights Medical Weight Loss Clinic including sales and official grand opening details, click here.
